Skip to main content

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Entero shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ento/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.42
-0.08 (-0.03%)
AAPL  264.08
-2.35 (-0.88%)
AMD  274.83
+16.71 (6.47%)
BAC  53.67
-0.65 (-1.19%)
GOOG  332.16
-2.31 (-0.69%)
META  673.43
+1.85 (0.28%)
MSFT  418.07
+6.85 (1.67%)
NVDA  198.25
-0.62 (-0.31%)
ORCL  177.16
+7.34 (4.33%)
TSLA  388.02
-3.93 (-1.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.